ES2537905B2 - Uso de 12- desoxiforboles para promover la proliferación de las células madre neurales - Google Patents

Uso de 12- desoxiforboles para promover la proliferación de las células madre neurales Download PDF

Info

Publication number
ES2537905B2
ES2537905B2 ES201301153A ES201301153A ES2537905B2 ES 2537905 B2 ES2537905 B2 ES 2537905B2 ES 201301153 A ES201301153 A ES 201301153A ES 201301153 A ES201301153 A ES 201301153A ES 2537905 B2 ES2537905 B2 ES 2537905B2
Authority
ES
Spain
Prior art keywords
proliferation
stem cells
neural stem
promote
deoxiforboles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201301153A
Other languages
English (en)
Other versions
ES2537905A2 (es
ES2537905R2 (es
Inventor
Carmen Castro González
Noelia GERIBALDI DOLDÁN
Maribel MURILLO CARRETERO
Jesús DOMINGUEZ RISCART
Purificación ORTIZ CUELLAR
Francisco GARCÍA BERNAL
Eugenia FLORES GIUBI
Rosario HERNÁNDEZ GALÁN
Antonio José MACÍAS SÁNCHEZ
Cristina VERÁSTEGUI ESCOLANO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cádiz
Original Assignee
University of Cádiz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cádiz filed Critical University of Cádiz
Priority to ES201301153A priority Critical patent/ES2537905B2/es
Priority to PCT/ES2014/000180 priority patent/WO2015086866A1/es
Publication of ES2537905A2 publication Critical patent/ES2537905A2/es
Publication of ES2537905R2 publication Critical patent/ES2537905R2/es
Application granted granted Critical
Publication of ES2537905B2 publication Critical patent/ES2537905B2/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Uso de 12-desoxiforboles para promover la proliferación de células madre neurales.#Esta invención está relacionada con el empleo de compuestos de la familia 12-desoxiforboles o una sal farmacológicamente activa de dichos compuestos, para favorecer la proliferación de precursores neurales o células madre neurales en cultivo. Adicionalmente, también se relaciona con el empleo de esta familia de compuestos para la elaboración de una composición farmacéutica útil en el tratamiento de enfermedades del sistema nervioso central que cursen con perdida neuronal.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50
imagen51
imagen52
imagen53
imagen54
imagen55
imagen56
imagen57
imagen58
imagen59
imagen60
imagen61
imagen62
imagen63
imagen64
imagen65
imagen66
imagen67

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
    imagen6
    imagen7
ES201301153A 2013-12-11 2013-12-11 Uso de 12- desoxiforboles para promover la proliferación de las células madre neurales Active ES2537905B2 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201301153A ES2537905B2 (es) 2013-12-11 2013-12-11 Uso de 12- desoxiforboles para promover la proliferación de las células madre neurales
PCT/ES2014/000180 WO2015086866A1 (es) 2013-12-11 2014-10-24 Uso de 12-desoxiforboles para promover la expansión de células madre neurales

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201301153A ES2537905B2 (es) 2013-12-11 2013-12-11 Uso de 12- desoxiforboles para promover la proliferación de las células madre neurales

Publications (3)

Publication Number Publication Date
ES2537905A2 ES2537905A2 (es) 2015-06-15
ES2537905R2 ES2537905R2 (es) 2015-06-29
ES2537905B2 true ES2537905B2 (es) 2015-10-14

Family

ID=53290863

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201301153A Active ES2537905B2 (es) 2013-12-11 2013-12-11 Uso de 12- desoxiforboles para promover la proliferación de las células madre neurales

Country Status (2)

Country Link
ES (1) ES2537905B2 (es)
WO (1) WO2015086866A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2916383B2 (es) * 2020-12-29 2023-12-13 Univ Cadiz Derivados de 12-desoxiforboles y usos de los mismos

Also Published As

Publication number Publication date
ES2537905A2 (es) 2015-06-15
ES2537905R2 (es) 2015-06-29
WO2015086866A1 (es) 2015-06-18

Similar Documents

Publication Publication Date Title
CY1123460T1 (el) Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
MX2019004616A (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
CL2016001895A1 (es) Compuestos
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
EP3895717C0 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COLORECTAL CANCER, COMPRISING WEISSELLA CIBARIA WIKIM28 AS ACTIVE SUBSTANCE
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2015003690A1 (es) Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.
ECSP14013284A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CO6791571A2 (es) Moduladores de la proteína tirosina quinasa 7 (ptk7) para el tratamiento diagnóstico o profilaxis de trastornos neoplásicos
AR093490A1 (es) Formas de dosificacion de ruxolitinib de liberacion sostenida
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
MX2020011100A (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar.
NI201600160A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
NI201600161A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
AR094241A1 (es) Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos
GT201700016A (es) [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
CL2017000117A1 (es) Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrófila.
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
CO2019008657A2 (es) Composición intranasal que comprende betahistina

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2537905

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20151014